Cancer genetics is a notoriously shifting ground. Having developed into a problem through mutations in the first place, cancer cells continue to mutate as the disease progresses. The most obvious problem from a clinical standpoint is that such mutations can render them resistant to therapy – a problem that plagues now-stalwarts like Gleevec (imatinib, Novartis AG) and new stars like Vemurafenib (PLX4032/RG7204, Plexxikon Inc./Roche AG) alike.